John Maki
Chief Executive Officer
Former CEO and founder of Bayesian Biotech, a personalized precision medicine company focused on rare pediatric diseases. Previous roles held by John include President of ConSynance, CEO of Vicus Therapeutics (a neuro-immuno-oncology company), Managing Director of TDI and Audax Group, Principal of Bain Capital and Consultant at Bain & Company. John also serves on Board of Trustees of BioNJ and Chair of the AI Committee.
John holds an A.B from Harvard.
Shuang Liu, PhD
Managing Member
Current CEO and Founder of ConSynance Therapeutics, a CNS/Rare-Disease company with a focus on Prader-Willi syndrome. Shuang is a scientist and entrepreneur with 25+ years of experience in drug R&D. Prior to ConSynance, Shuang led discovery teams at Curia to deliver multiple NCEs into clinical trials.
Shuang holds a Ph.D. in Organic Chemistry from the University of Georgia.
Bob Smith
Member
Former Senior VP of Gene Therapy & Rare Disease and Commercial Strategy & Innovation at Pfizer, Bob has 30+ years of experience including alliance management, business development, and R&D. His career is marked by significant roles in global M&A, BD, and contributions to various business units. Bob is the board member of multiple companies and industry associations.
Bob holds a BS in Neuroscience and an MBA from the University of Rochester.
Clinical & Scientific Advisors
